iX Biopharma Ltd. has been recognised in The Straits Times’ Singapore’s Fastest Growing Companies 2026 list, compiled in partnership with global research firm Statista. This is the third consecutive year the company has received this accolade.

• Growth Drivers – Drug Delivery Platform: The company’s proprietary WaferiX® sublingual drug delivery platform remains a key engine of growth, expanding its pharmaceutical offerings and helping drive revenue momentum.
• U.S. Expansion Strategy: iX Biopharma is executing a capital-light expansion approach in the United States, including distribution through compounding pharmacies and potential collaborations around its pipeline products.
• Investor Implications: The repeat recognition and strategic initiatives in the U.S. market may bolster iX Biopharma’s visibility with investors, partners, and customers, supporting long-term growth prospects.

This summary is based on a publication on Minichart.